Engineering a Human Organ for Dry Storage

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,802.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43AR049948-01
Agency Tracking Number:
AR049948
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
STRATATECH CORPORATION
STRATATECH CORPORATION, 505 S ROSA RD, MADISON, WI, 53719
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PAUL CONRAD
(608) 441-2750
PCONRAD@STRATATECHCORP.COM
Business Contact:
ROBERT BARNARD
(608) 441-2756
RBARNARD@STARATECHOCRP.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Tissue engineering is a field with tremendous untapped potential, current revenues ($232 million in 2000, Genetic Engineering News 9/15/01) fall far short of the estimated market of $100 billion (Barron's, 5/15/00). This gap is in large part due to the significant barriers of short shelf life and high storage cost. Stratatech proposes to develop technology overcoming these hurdles using genetic manipulations of source cells coupled with recent advances in preservation solution engineering to create methods enabling room temperature storage of living cells and organs. Currently tissues are preserved by slow freezing during which they suffer numerous damaging effects. Rapid freezing or vitrification avoids these issues by preserving samples in an amorphous glass, but vitrification can give rise to lethal intracellular ice formation. Agents such as trehalose, a disaccharide of glucose, enhance the vitrification properties of preservation solutions; unfortunately, trehalose cannot penetrate cell membranes so novel methods must be used to deliver intracellular trehalose. Furthermore, until recently, vitrification of medically useful sample sized was not practical, but recent work has shown that careful engineering of the preservation solution can greatly enhance trehalose's ability to raise glass transition temperatures. Stratatech is developing a line of human keratinocytes for therapeutic applications called NIKS cells. NIKS cells are an ideal vehicle for this proposal in that they can be perpetually cultured in vitro and they can be used to manufacture a functional human organ. In addition they are pathogen-free, non-tumorigenic and they recapitulate the correct architecture of human skin. NIKS cells and skin tissue grown from them are capable of stable genetic modifications making it possible to optimize their survival in the dry state.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government